Using a MS-based immunopeptidomics approach, we characterized the effect of HDAC6 inhibitors on the antigenic landscape of multiple myeloma cells and identified canonical antigens and neoantigens upregulated by proteasome activation. Here, HDAC6 is linked to AL amyloidosis.